HC Wainwright & Co. Maintains Buy on Coherus BioSciences, Lowers Price Target to $26
HC Wainwright & Co. analyst Douglas Tsao maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and lowers the price target from $30 to $26.
Coherus BioSciences Q4 EPS $(0.60) Beats $(0.84) Estimate, Sales $45.35M Miss $47.68M Estimate
Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(0.84) by 28.57 percent. This is a 30.43 percent decrease over losses of $(0.46) per share
Earnings Scheduled For March 6, 2023
Companies Reporting Before The Bell
• Passage Bio (NASDAQ:PASG) is estimated to report earnings for its fourth quarter.
Junshi Biosciences And Coherus Biosciences Announced Results Of A Final Analysis Of Overall Survival From Jupiter-02 Phase 3 Trial Of Toripalimab Plus Gemcitabine Plus Cisplatin As The First-line Treatment Recurrent Or Metastatic Nasopharyngeal Carcino…
This final analysis demonstrated a statistically significant and clinically meaningful improvement in overall survival in nasopharyngeal carcinoma patients treated with toripalimab plus chemotherapy compared to
Coherus Agrees to Acquire Exclusive U.S. Commercial Rights To Eylea Biosimilar FYB203 From Klinge Biopharma; Terms Not Disclosed
Coherus BioSciences, Inc. ((Coherus or Coherus BioSciences, NASDAQ:CHRS) announced today that it has executed a binding term sheet with Klinge Biopharma GmbH (Klinge Biopharma) for the exclusive commercialization rights
Why Hoth Therapeutics Shares Are Trading Higher By More Than 130%? Here Are 60 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Hoth Therapeutics, Inc. (NASDAQ: HOTH) shares jumped 131.5% to $10.19 after the FDA accepted the IND application for HT-001.
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 325 companies set new 52-week lows.
Tesla, NIO And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded mixed, with the Dow Jones gaining over 100 points on Tuesday. Here are some big stocks recording losses in today’s session.
Biogen’s 2nd Alzheimer’s Antibody, BeiGene’s Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Biopharma stocks were not immune to the broader market downturn seen for much of 2022.
Junshi Biosciences and Coherus Announced FDA Has Been Unable to Travel to China to Conduct the Required Site Inspection Resulting in Delayed Action on the BLA for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. ("Coherus", Nasdaq: CHRS) today announced that the companies have not received an action letter from the U.S.